New hope for older leukemia patients: engineered immune cells aim to keep cancer away
NCT ID NCT05707273
First seen Apr 25, 2026 · Last updated May 06, 2026 · Updated 3 times
Summary
This early-stage trial tests whether a personalized cell therapy (CAR T-cells) can safely prevent relapse in older adults with B-cell acute lymphoblastic leukemia who are already in first remission. About 18 participants will receive their own immune cells, modified in a lab to target and destroy leukemia cells. The main goals are to find the safest dose and identify side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
Conditions
Explore the condition pages connected to this study.